Новости и публикации о препарате Мексидол®

From March 9 to March 15, the World Wide Week Week is held around the world, aimed at increasing the awareness of the disease, which remains one of the leading causes of irreversible blindness. Glaucoma is a chronic progressive disease of the optic nerve, requiring a comprehensive approach to treatment.

Scientists from the national center of cardiovascular diseases in Beijing compared the effectiveness of a decrease in systolic pressure levels to 120 mm Hg. and up to 140 mm Hg. The results of the ESPRIT study were presented at the scientific session of the American AHA-2023 Association and published on the Medscape portal.

Neuroprotection should be an integral part of the management of patients with hypertension. It is recommended to supplement the drug treatment algorithm for patients with hypertension by including ethylmethylhydroxypyridine succinate (Mexidol®⁾in the clinical guidelines for "Arterial Hypertension in Adults" (I10/I11/I12/I13/I15, according to ICD-10).

NPK PHARMASOFT LLC announces the inclusion of a new indication – attention deficit hyperactivity disorder in children (aged 6 years and over), including hyperactivity, attention deficit, and impulsivity – in the instructions for medical use of the medicinal product Mexidol®^film -coated tablets, 125 mg.

Dear colleagues, we inform you about the inclusion of a new indication - attention deficit syndrome with hyperactivity (ADHD) in children aged 6 to 12 years, including hyperactivity, impaired attention, impulsiveness.

With the high -speed rhythm of life that is now, many patients, especially working age, do not always manage to find time in their dense schedule for visiting the procedural office. Nevertheless, they also get sick and they can also diagnose serious pathologies that will require the purpose of the course of effective therapy, including Injection forms.

Influenza is an acute infectious disease that affects both the upper and lower respiratory tract, the causative agent of which is the virus.

The "Library" - "Evidence Base" section contains the article "Results of a multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of Mexidol in the treatment of attention deficit hyperactivity disorder in children (MEGA)."

The results of an international, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of sequential therapy with Mexidol^® and Mexidol^® FORTE 250 in patients with chronic cerebral ischemia (the MEMO study), conducted in full compliance with international ethical and scientific standards for the design and conduct of research involving human subjects (GCP), were published in the Korsakov Journal of Neurology and Psychiatry, 2021; 121(11):7–16, a leading peer-reviewed journal for neurologists and psychiatrists in Russia, recognized by the Higher Attestation Commission (HAC).

To fully utilize the therapeutic potential of Mexidol®^, sequential long-term therapy is recommended (EPICA¹, 2017): initially 14 days of injections (saturation phase), followed by a transition to Mexidol® or Mexidol® FORTE 250 tablets^for 2^months (therapeutic effect maximization phase). Therapy is administered 2-3 times per year or during periods of exacerbation.